Texas is moving forward with a first-of-its-kind, state-funded research initiative into ibogaine, a psychedelic compound being studied as a potential treatment for PTSD, traumatic brain injuries, and addiction.
The effort stems from legislation signed into law by Governor Greg Abbott in 2025, creating a grant program to support clinical trials aimed at securing federal approval for ibogaine as a medical treatment. The state has committed up to $50 million in funding, with additional private investment expected to match that amount.
A major piece of the research will involve institutions across Texas—including University of Texas at Austin—giving the capital city a direct role in what officials describe as a groundbreaking statewide collaboration. Researchers in Austin are expected to focus specifically on traumatic brain injury, particularly among veterans.
The multi-institution effort, known as the IMPACT program, will be led by UTHealth Houston and University of Texas Medical Branch, alongside a network of universities and medical centers across the state.
Supporters say the initiative could position Texas as a national leader in psychedelic research, particularly as demand grows for new treatments targeting mental health challenges.
“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives,” said UTHealth Houston President Dr. Melina Kibbe.
State lawmakers behind the measure say the focus is especially urgent for veterans.
“Texas has a responsibility to pursue solutions… especially when the stakes involve… the invisible wounds carried by so many of our veterans,” said State Sen. Tan Parker, who sponsored the legislation.
Veterans advocacy groups have also pushed for the research, arguing that many former service members are running out of effective treatment options.
“The Texas Ibogaine Initiative is a monumental step forward… for veterans who have long been underserved,” said Amber Capone, CEO of Veterans Exploring Treatment Solutions.
Ibogaine, derived from a plant native to Central Africa, is currently classified as a Schedule I drug in the United States, meaning it is illegal for general use. However, early studies and anecdotal reports suggest it may help reset brain function and alleviate symptoms tied to trauma and addiction.
Despite the optimism, researchers emphasize that the drug must undergo rigorous clinical trials to determine both its safety and effectiveness before it can be approved for widespread medical use.
If successful, the Texas-led effort—anchored in part by research happening in Austin—could help pave the way for federal approval and broader access to a new class of treatments for PTSD and other neurological conditions.
